文献速递重症综合管理与镇静镇痛

重症监护中的卫生经济学评价:一项更新的系统综述

Health Economic Evaluations in Intensive Care: An Updated Systematic Review.
PubMed 文献 · Crit Care Explor · 2025-07-16
一句话结论1993至2023年重症监护领域仅219项卫生经济学评价,ICER从优势到每挽救生命753874美元,异质性大且低收入和中等收入国家证据稀缺。

该系统综述检索六个学术数据库,纳入1993至2023年发表的成人ICU干预全卫生经济学评价(成本效果、成本效用、成本效益、成本最小化分析),排除儿科、动物和撤机中心研究。共纳入219项研究,近十年发表量显著上升,97%的研究报告质量良好至优秀,58%为模型研究。增量成本效果比(ICER)从优势(更有效且更便宜)到每挽救生命753874美元;每质量调整生命年成本和每获得生命年成本的ICER从优势到被支配(更贵且更无效)。仅3项(1%)研究来自低收入和中等收入国家,作者建议未来在这些地区开展研究并增加基于试验的研究。

要点

  • 1993至2023年ICU成人干预的卫生经济学评价共219项,近十年发表量显著上升,但相对其他医学领域仍稀缺。
  • 97%的研究报告质量良好至优秀(按 Consolidated Health Economic Evaluation Reporting Standards 清单评估)。
  • ICER从优势(更有效且更便宜)到每挽救生命753874美元;每质量调整生命年成本和每获得生命年成本的ICER从优势到被支配。
  • 仅3项(1%)研究来自低收入和中等收入国家,58%为模型研究而非基于试验。
  • 作者建议未来在低收入和中等收入国家开展研究并增加基于试验的研究。

适用人群与场景

  • 成人ICU患者接受的干预措施;排除儿科、动物和撤机中心研究。

研究设计与关键结果

  • 系统综述纳入1993至2023年发表的219项成人ICU干预卫生经济学评价(成本效果、成本效用、成本效益、成本最小化分析),近十年发表量显著上升。
  • 97%的研究报告质量良好至优秀(按 Consolidated Health Economic Evaluation Reporting Standards 清单评估)。
  • ICER从优势(更有效且更便宜)到每挽救生命753874美元。
  • 每质量调整生命年成本和每获得生命年成本的ICER均从优势到被支配(更贵且更无效)。
  • 仅3项(1%)研究来自低收入和中等收入国家,58%为模型研究。

证据类型、等级与局限

  • 证据类型:系统综述,检索六个学术数据库(Ovid包括MEDLINE、Embase和EBM Reviews中的Health Technology Assessments与NHS Economic Evaluation Database,EBSCO包括CINAHL和EconLit,以及Web of Science)。
  • 研究质量用 Consolidated Health Economic Evaluation Reporting Standards 清单评估,97%的研究报告质量良好至优秀。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议未来在低收入和中等收入国家开展研究并增加基于试验的研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Intensive care is a critical but resource-intensive component of healthcare. Health economic evaluations, such as cost-effectiveness analyses (CEAs), offer valuable insights for decision-making by weighing the costs and benefits of various healthcare interventions. We aimed to identify and summarize the existing health economic evaluations within intensive care and identify areas for future research.

DATA SOURCES: We searched six academic databases to identify full health economic evaluations of ICU interventions published between 1993 and 2023. Databases included: Ovid (MEDLINE, Embase, and evidence based medicine (EBM) Reviews [Health Technology Assessments and National Health Service (NHS) Economic Evaluation Database]), EBSCO (CINAHL and EconLit), and Web of Science.

STUDY SELECTION: Health economic evaluations of interventions for adult patients in the ICU were included. Economic evaluations include CEAs, cost-utility, cost-benefit, and cost-minimization analyses, while pediatric, animal and weaning center studies were excluded.

DATA EXTRACTION: Data were extracted by two independent reviewers. Study quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards checklist.

DATA SYNTHESIS: We identified 219 relevant studies published between 1993 and 2023, with a significant rise in publications over the last decade. Most studies (97%) had good to excellent reporting quality. Incremental cost-effectiveness ratios (ICERs) ranged from dominant (more effective and less expensive) to $753,874 per life saved. ICERs for both cost per quality-adjusted life-years and cost per life-year gained ranged from dominant to dominated (more costly and less effective). Three studies (1%) were published in low- and middle-income countries (LMICs) and 58% of studies were modeling studies.

CONCLUSIONS: Despite the importance of economic evidence in healthcare decision-making, there is a relative scarcity of cost-effectiveness studies in intensive care compared with other medical fields. Available economic evaluations in intensive care are characterized by significant heterogeneity. The wide range of ICERs for life saved, life-years gained, and quality-adjusted life-years reflects the diversity of ICU patients, interventions, and evaluation methods. Future research in LMICs and increasing trial-based research is recommended.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Nguyen CL, Tse WC, Carney TM, et al. Health Economic Evaluations in Intensive Care: An Updated Systematic Review. Crit Care Explor. 2025. PMID: 40673428. doi:10.1097/CCE.0000000000001288

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。